Background : Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients.

苯司汀，具有烷化剂和嘌呤类似的双相功能可以在转移性乳腺癌（MBC）患者中发挥作。

Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.

依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数检查，以监测骨髓发或继发性白血病的发生迹象。